The RNA exosome component hRrp6 is a target for 5-fluorouracil in human cells

Molecular Cancer Research

Volumn 6, Issue 6, 2008, Pages 990-995

  Kammler, Susanne ^a,b   Lykke Andersen, Søren ^a   Jensen, Torben Heick ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Exiqon AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXONUCLEASE; FLUOROURACIL; PROTEIN RRP6; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; EXORIBONUCLEASE; EXOSC10 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; EXOSOME; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; CELL LINE; DRUG ANTAGONISM; ENDOGENOUS RETROVIRUS; GENETICS; METABOLISM; RNA STABILITY;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE; ENDOGENOUS RETROVIRUSES; EXORIBONUCLEASES; FLUOROURACIL; HELA CELLS; HUMANS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER;

EID: 50349097798     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2217     Document Type: Article

References (26)

1. Dziembowski A, Lorentzen E, Conti E, Seraphin B. A single subunit, Dis3, is essentially responsible for yeast exosome core activity. Nat Struct Mol Biol 2007;14:15-22.
2. Liu Q, Greimann JC, Lima CD. Reconstitution, activities, and structure of the eukaryotic RNA exosome. Cell 2006;127:1223-37.
3. Schneider C, Anderson JT, Tollervey D. The exosome subunit Rrp44 plays a direct role in RNA substrate recognition. Mol Cell 2007;27:324-31.
4. Mitchell P, Tollervey D. Musing on the structural organization of the exosome complex. Nat Struct Biol 2000;7:843-6.
5. Schilders G, van Dijk E, Raijmakers R, Pruijn GJ. Cell and molecular biology of the exosome: how to make or break an RNA. Int Rev Cytol 2006;251:159-208.
6. Lejeune F, Li X, Maquat LE. Nonsense-mediated mRNA decay in mammalian cells involves decapping, deadenylating, and exonucleolytic activities. Mol Cell 2003;12:675-87.
7. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
8. Fang F, Hoskins J, Butler JS. 5-Fluorouracil enhances exosome-dependent accumulation of polyadenylated rRNAs. Mol Cell Biol 2004;24:10766-76.
9. Lum PY, Armour CD, Stepaniants SB, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 2004;116:121-37.
10. Giaever G, Flaherty P, Kumm J, et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci U S A 2004;101:793-8.
11. Cory JG, Breland JC, Carter GL. Effect of 5-fluorouracil on RNA metabolism in Novikoff hepatoma cells. Cancer Res 1979;39:4905-13.
12. Greenhalgh DA, Parish JH. Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells. Br J Cancer 1990;61:415-9.
13. Greenhalgh DA, Parish JH. Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol 1989;25:37-44.
14. van Dijk EL, Schilders G, Pruijn GJ. Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways. RNA 2007;13:1027-35.
15. Stauffer Y, Theiler G, Sperisen P, Lebedev Y, Jongeneel CV. Digital expression profiles of human endogenous retroviral families in normal and cancerous tissues. Cancer Immun 2004;4:2.
16. de Parseval N, Lazar V, Casella JF, Benit L, Heidmann T. Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol 2003;77:10414-22.
17. Engelbrecht C, Ljungquist I, Lewan L, Yngner T. Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma. Biochem Pharmacol 1984;33:745-50.
18. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:934-47.
19. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31.
20. Yang XF, Wu CJ, Chen L, et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002;62:5517-22.
21. Hieronymus H, Yu MC, Silver PA. Genome-wide mRNA surveillance is coupled to mRNA export. Genes Dev 2004;18:2652-62.
22. + gene encoding a mitotic-control protein and its overexpression in cancer cells with progressive phenotype. Cancer Res 1997;57:921-5.
23. Johnston PG, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 2001;12:639-46.
24. Villesen P, Aagaard L, Wiuf C, Pedersen FS. Identification of endogenous retroviral reading frames in the human genome. Retrovirology 2004;1:32.
25. Brouwer R, Allmang C, Raijmakers R, et al. Three novel components of the human exosome. J Biol Chem 2001;276:6177-84.
26. Pinol-Roma S, Choi YD, Matunis MJ, Dreyfuss G. Immunopurification of heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA-binding proteins. Genes Dev 1988;2:215-27.